{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:22:09Z","timestamp":1793928129509,"version":"4.8.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032350","name":"Alligator Bioscience","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032350","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.xcrm.2025.102407","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T23:49:29Z","timestamp":1759880969000},"page":"102407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1"],"prefix":"10.1016","volume":"6","author":[{"given":"Jean-Luc","family":"Van Laethem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Geboes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Borbath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Macarulla Mercade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Cassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Prenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Mitry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Pilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Feliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Rodriguez Garrote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Antonio","family":"Pazo-Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin Enell","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Nordbladh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Gomez","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6687-1250","authenticated-orcid":false,"given":"Peter","family":"Ellmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yago","family":"Pico de Coa\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet Vijay","family":"Ambarkhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Beatty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"O'Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102407_bib1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic Cancer: A Review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2025.102407_bib2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/14796694.2024.2435253","article-title":"Real-world clinical outcomes and economic burden of metastatic pancreatic ductal adenocarcinoma: a systematic review","volume":"21","author":"Cockrum","year":"2025","journal-title":"Future Oncol."},{"key":"10.1016\/j.xcrm.2025.102407_bib3","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2025.102407_bib4","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1053\/j.gastro.2018.12.038","article-title":"Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities","volume":"156","author":"Balachandran","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.xcrm.2025.102407_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12935-018-0585-0","article-title":"Targeting dendritic cells in pancreatic ductal adenocarcinoma","volume":"18","author":"Deicher","year":"2018","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.xcrm.2025.102407_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102655","article-title":"Recent insights into the biology of pancreatic cancer","volume":"53","author":"Yao","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.xcrm.2025.102407_bib7","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102407_bib8","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1053\/j.gastro.2024.01.013","article-title":"Intra-tumoral cell neighborhoods coordinate outcomes in pancreatic ductal adenocarcinoma","volume":"166","author":"Wattenberg","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.xcrm.2025.102407_bib9","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/s41467-024-55424-2","article-title":"Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms","volume":"16","author":"Sivakumar","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102407_bib10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14737140.2017.1270208","article-title":"Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists","volume":"17","author":"Beatty","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.xcrm.2025.102407_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.gastro.2015.04.010","article-title":"Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4\/80(+) Extratumoral Macrophages","volume":"149","author":"Beatty","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.xcrm.2025.102407_bib12","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","article-title":"Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer","volume":"27","author":"Byrne","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102407_bib13","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padron","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.xcrm.2025.102407_bib14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/1078-0432.CCR-23-0475","article-title":"A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy","volume":"30","author":"Weiss","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102407_bib15","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-15-1032","article-title":"IFN\u03b3 and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma","volume":"6","author":"Long","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102407_bib16","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(24)00263-8","article-title":"Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b\/2 study","volume":"25","author":"Van Laethem","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102407_bib17","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1200\/JCO.2020.38.15_suppl.4641","article-title":"Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC): Clinical\/molecular correlations and real-world outcomes across standard therapies","volume":"38","author":"Hendifar","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102407_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2016.18","article-title":"KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma","volume":"7","author":"Bournet","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.xcrm.2025.102407_bib19","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1200\/JCO.2023.41.16_suppl.4020","article-title":"Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome","volume":"41","author":"Ardalan","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102407_bib20","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s43018-023-00628-6","article-title":"Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC","volume":"4","author":"Zhou","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2025.102407_bib21","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2025.102407_bib22","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-19-3724","article-title":"GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer","volume":"26","author":"O'Kane","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102407_bib23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma","volume":"32","author":"Raphael","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102407_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102407_bib25","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1038\/s41467-024-49915-5","article-title":"Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma","volume":"15","author":"Till","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102407_bib26","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.2024.42.16_suppl.2510","article-title":"Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials","volume":"42","author":"Toledo","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102407_bib27","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-18-0386","article-title":"Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab","volume":"24","author":"Raja","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102407_bib28","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1373\/clinchem.2017.283721","article-title":"Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma","volume":"64","author":"Kim","year":"2018","journal-title":"Clin. Chem."},{"key":"10.1016\/j.xcrm.2025.102407_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2022.03.033","article-title":"High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity","volume":"169","author":"Karamitopoulou","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102407_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100336","article-title":"Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers","volume":"7","author":"Palmeri","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.xcrm.2025.102407_bib31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102407_bib32","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1038\/ncomms7744","article-title":"Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets","volume":"6","author":"Witkiewicz","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102407_bib33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature11547","article-title":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes","volume":"491","author":"Biankin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102407_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: A Precision Oncology Knowledge Base","volume":"1","author":"Chakravarty","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.xcrm.2025.102407_bib35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","article-title":"Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer","volume":"14","author":"Suehnholz","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102407_bib36","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1158\/1078-0432.CCR-24-1164","article-title":"Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer","volume":"30","author":"Singh","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102407_bib37","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102407_bib38","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102407_bib39","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102407_bib40","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1158\/1078-0432.CCR-24-1660","article-title":"Facts and hopes of CD40 agonists as a cancer immunotherapy","volume":"31","author":"McVey","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102407_bib41","first-page":"1","article-title":"Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy","volume":"17","author":"Enell Smith","year":"2021","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.xcrm.2025.102407_bib43","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study","volume":"22","author":"O'Hara","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102407_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41698-024-00505-0","article-title":"Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma","volume":"8","author":"Yousef","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.xcrm.2025.102407_bib42","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102407_bib45","first-page":"2182","article-title":"Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11)","volume":"7","author":"Mathijssen","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102407_bib46","first-page":"2012","article-title":"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans","volume":"6","author":"Santos","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102407_bib47","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/BF00689205","article-title":"Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan","volume":"36","author":"Rivory","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.102407_bib48","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1074\/jbc.M114.590364","article-title":"Inhibition of transient receptor potential channel 5 reverses 5-Fluorouracil resistance in human colorectal cancer cells","volume":"290","author":"Wang","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2025.102407_bib49","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.3748\/wjg.v24.i29.3222","article-title":"ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?","volume":"24","author":"Adamska","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.xcrm.2025.102407_bib50","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.145389","article-title":"Systemic inflammation is a determinant of outcomes to CD40 agonist-based therapy in pancreatic cancer patients","volume":"6","author":"Wattenberg","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2025.102407_bib51","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146314","article-title":"TNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy","volume":"6","author":"Stone","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2025.102407_bib52","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1158\/1078-0432.CCR-13-1320","article-title":"A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma","volume":"19","author":"Beatty","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102407_bib53","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3858\/emm.2009.41.5.038","article-title":"ICAM-1\/LFA-1 interaction contributes to the induction of endothelial cell-cell separation: implication for enhanced leukocyte diapedesis","volume":"41","author":"Wee","year":"2009","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.xcrm.2025.102407_bib54","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00262-008-0474-9","article-title":"CD54 is a surrogate marker of antigen presenting cell activation","volume":"57","author":"Sheikh","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2025.102407_bib55","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1158\/1078-0432.CCR-14-0913","article-title":"The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity","volume":"21","author":"Mangsbo","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102407_bib56","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3389\/fmicb.2019.01057","article-title":"The Role of Interleukin 6 During Viral Infections","volume":"10","author":"Velazquez-Salinas","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.xcrm.2025.102407_bib57","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102407_bib58","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102407_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/imt2.43","article-title":"Complex heatmap visualization","volume":"1","author":"Gu","year":"2022","journal-title":"Imeta"},{"key":"10.1016\/j.xcrm.2025.102407_bib60","article-title":"Gene Set Knowledge Discovery with Enrichr","volume":"1","author":"Xie","year":"2021","journal-title":"Curr. Protoc."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266637912500480X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266637912500480X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:13:15Z","timestamp":1788563595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266637912500480X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S266637912500480X"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102407","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102407","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102407"}}